• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

    12/20/24 7:45:00 AM ET
    $FLR
    $GM
    $LLY
    $STLA
    Military/Government/Technical
    Industrials
    Auto Manufacturing
    Industrials
    Get the next $FLR alert in real time by email

    Thanks largely to some blockbuster projects, the value of industrial construction presently underway in Indiana and tracked by Industrial Info exceeds $39 billion. The projects cover a range of sectors from pharmaceutical-biotech projects to cutting-edge data centers.

    By far the largest project presently underway in the state is pharmaceutical giant Eli Lilly and Company's ((LLY) (Indianapolis, Indiana) expansion of its campus in Lebanon, about 30 miles from Lilly's headquarters in Indianapolis. The project broke ground in the summer of 2023, with engineering, procurement and construction (EPC) firm Fluor Corporation ((FLR) (Irving, Texas) leading the work.

    Other multibillion projects in the state involve the automotive sector, specifically the manufacture of the batteries that power electric vehicles (EVs). Both General Motors Company ((GM) (GM) (Detroit, Michigan) and Stellantis NV ((STLA) (Hoofddorp, Netherlands) are constructing battery plants in the state.

    Click here to view the rest of this article.

    Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 Trillion (USD).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241220541310/en/

    Get the next $FLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLR
    $GM
    $LLY
    $STLA

    CompanyDatePrice TargetRatingAnalyst
    General Motors Company
    $GM
    3/25/2026$96.00Peer Perform → Outperform
    Wolfe Research
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    General Motors Company
    $GM
    3/4/2026$105.00Buy
    BofA Securities
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Stellantis N.V.
    $STLA
    2/9/2026Underperform → Peer Perform
    Wolfe Research
    Stellantis N.V.
    $STLA
    2/3/2026$10.90Overweight → Equal-Weight
    Morgan Stanley
    General Motors Company
    $GM
    1/29/2026$98.00Hold → Buy
    DZ Bank
    More analyst ratings

    $FLR
    $GM
    $LLY
    $STLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLR
    $GM
    $LLY
    $STLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLR
    $GM
    $LLY
    $STLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    General Motors upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded General Motors from Peer Perform to Outperform and set a new price target of $96.00

    3/25/26 8:23:38 AM ET
    $GM
    Auto Manufacturing
    Industrials

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on General Motors with a new price target

    BofA Securities resumed coverage of General Motors with a rating of Buy and set a new price target of $105.00

    3/4/26 8:37:45 AM ET
    $GM
    Auto Manufacturing
    Industrials

    $FLR
    $GM
    $LLY
    $STLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,976 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    3/17/26 4:32:31 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 16,817 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    3/17/26 4:31:37 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,259 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    3/17/26 4:30:41 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLR
    $GM
    $LLY
    $STLA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fluor Corporation

    SCHEDULE 13G/A - FLUOR CORP (0001124198) (Subject)

    3/26/26 6:38:04 PM ET
    $FLR
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by General Motors Company

    SCHEDULE 13G/A - General Motors Co (0001467858) (Subject)

    3/26/26 6:36:23 PM ET
    $GM
    Auto Manufacturing
    Industrials

    General Motors Company filed SEC Form 8-K: Creation of a Direct Financial Obligation

    8-K - General Motors Co (0001467858) (Filer)

    3/23/26 4:01:13 PM ET
    $GM
    Auto Manufacturing
    Industrials

    $FLR
    $GM
    $LLY
    $STLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

    In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78% experienced significant itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients80% of patients achieved durable results without the need for topical corticosteroidsINDIANAPOLIS, March 27, 2026 /PRNewswire/ -- New long-term data show Eli Lilly and Company's (NYSE:LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-

    3/27/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIXPACK-powered 2026 Dodge Charger Scat Pack Wins Two Top Honors at 2026 TAWA Texas Auto Roundup

    AUBURN HILLS, Mich., March 26, 2026 /PRNewswire/ -- 2026 Dodge Charger Scat Pack takes home Performance Vehicle of Texas and Best Interior awards at Texas Auto Writers Association (TAWA) Texas Auto RoundupTAWA members praised the Charger Scat Pack's balance of power, character and everyday usabilitySIXPACK-powered Charger Scat Pack delivers 550 horsepower, 531 lb.-ft. of torque, moves from 0-60 mph in 3.9 seconds with a quarter-mile elapsed time of 12.2 secondsDriver-focused, award-winning interior design enhances SIXPACK-powered Charger while also providing best-in-class passen

    3/26/26 11:00:00 AM ET
    $STLA
    Auto Manufacturing
    Industrials

    Jeep® Brand Rolls Into the 60th Easter Jeep Safari, Celebrating Decades of Trail-built Toughness

    AUBURN HILLS, Mich., March 26, 2026  /PRNewswire/ -- Jeep® brand and Jeep Performance Parts (JPP) by Mopar head to the 60th anniversary of Easter Jeep Safari in Moab, Utah, (March 28 to April 5) with even more vehicles and experiences for Jeep customers and off-road enthusiasts  All-new Jeep and JPP custom concept builds pay homage to Jeep brand's roots while defining the future of off-roading Land preservation and cleanup efforts at Fins and Things trail are led by Jeep brand and JPP employees, Red Rock 4-Wheelers and the Bureau of Land Management Official Jeep brand home base

    3/26/26 9:00:00 AM ET
    $STLA
    Auto Manufacturing
    Industrials

    $FLR
    $GM
    $LLY
    $STLA
    Financials

    Live finance-specific insights

    View All

    Stellantis Reports Full Year 2025 Financial Results

    Stellantis Reports Full Year 2025 Financial ResultsDecisive Reset to Meet Customer Preferences Focus on Strong Execution in 2026 Net revenues of €153.5 billion, down 2% compared to 2024, mainly due to FX headwinds and also from H1 2025 net pricing declinesNet loss of €22.3 billion due to €25.4 billion of full year unusual charges, primarily reflects a strategic shift to put customer preferences and freedom-of-choice back at the heart of the Company's plansAdjusted operating loss(2) of €842 million with AOI margin(3) of (0.5)%, AOI negatively impacted by a number of specific itemsIndustrial free cash flows(4) were negative €4.5 billionH2 2025, the first full 6 months of the renewed leadershi

    2/26/26 2:04:07 AM ET
    $STLA
    Auto Manufacturing
    Industrials

    Fluor Reports Fourth Quarter and Full Year 2025 Results

    Full year 2025 share repurchases of $754 million; $1.4 billion planned for 2026 Full year new awards of $12.0 billion; 87% reimbursable Ending Backlog of $25.5 billion; 81% reimbursable Received $1.35 billion in Q1 2026 for NuScale share sales Fluor Corporation (NYSE:FLR) announced financial results for its year ended December 31, 2025. "Our growing confidence in capturing significant EPC awards in 2026 and into 2027 is supported by an improving capital spending environment and increasing client commitments," said Jim Breuer, chief executive officer of Fluor. "Furthermore, I am pleased that the monetization of our NuScale investment is progressing well and that we are returni

    2/17/26 6:50:00 AM ET
    $FLR
    Military/Government/Technical
    Industrials

    Stellantis to Announce Full Year 2025 Results on February 26

    Stellantis to Announce Full Year 2025 Results on February 26  AMSTERDAM, February 16, 2026 - Stellantis N.V. announced today that its Full Year 2025 Results will be released on Thursday, February 26, 2026. A live audio webcast and conference call for Full Year 2025 Results will take place on Thursday, February 26, 2026, at 2:00 p.m. CET / 8:00 a.m. EST. The related press release and presentation materials are expected to be posted under the Investors section of the Stellantis corporate website at approximately 8:00 a.m. CET / 2:00 a.m. EST on Thursday, February 26, 2026. Details for accessing this presentation are available under the Investors section of the corporate website. For those

    2/16/26 8:02:12 AM ET
    $STLA
    Auto Manufacturing
    Industrials

    $FLR
    $GM
    $LLY
    $STLA
    Leadership Updates

    Live Leadership Updates

    View All

    Fluor Announces Appointment of Robert G. (Bob) Card to its Board of Directors

    Fluor Corporation (NYSE:FLR) announced today that Robert G. (Bob) Card, former President and CEO of SNC‑Lavalin and a seasoned global engineering and construction executive, has been elected to its Board of Directors effective March 4, 2026. Card will serve on the Board's Audit Committee and Commercial Strategies and Operational Risk Committee. Card's appointment brings the total number of Fluor Board members to 12 of whom 10 are independent. With more than three decades of top‑level management experience across public and private sectors, he contributes broad industry, operational and government expertise. "Bob Card's extensive leadership across the engineering, construction and projec

    3/9/26 6:51:00 AM ET
    $FLR
    Military/Government/Technical
    Industrials

    Fluor Announces Retirement of Executive Chairman, David E. Constable, and Appointment of James T. (Jim) Hackett as Chairman of the Board

    Fluor Corporation (NYSE:FLR) today announced that David E. Constable, Executive Chairman, will step down from the Board of Directors following the Annual Shareholders Meeting on May 6, 2026. James T. (Jim) Hackett, the company's Lead Independent Director, will assume the role of Chairman of the Board on May 5, 2026. Constable's connection to Fluor spans 44 years. He began his career with the company in 1982, advancing through a series of global leadership roles that shaped Fluor's operational and commercial capabilities. After joining the Fluor Board in 2019, he chaired the Commercial Strategies and Operational Risk Committee, later becoming Chief Executive Officer (CEO) in 2021 and Chair

    3/9/26 6:50:00 AM ET
    $FLR
    Military/Government/Technical
    Industrials

    Graco Inc. Announces Appointment of Sanjiv Gupta as Chief Financial Officer and Treasurer; David M. Lowe to Retire After Three Decades of Service

    Graco Inc. (NYSE:GGG) announced today that it has appointed Sanjiv Gupta as Chief Financial Officer and Treasurer, effective April 15, 2026. Gupta will succeed David M. Lowe in the role, who recently informed the company of his intention to retire after a more than thirty-year career with Graco. Gupta joins Graco from General Motors Company (NYSE:GM), where he has spent more than twenty years in various finance and operating roles of increasing leadership responsibility, most recently as Vice President & Chief Financial Officer, GM International. Having also served as Executive Director, Corporate Financial Planning and Analysis, and President and Managing Director, GM India, among other

    3/2/26 5:15:00 PM ET
    $GGG
    $GM
    Fluid Controls
    Industrials
    Auto Manufacturing

    $FLR
    $GM
    $LLY
    $STLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fluor Corporation

    SC 13G/A - FLUOR CORP (0001124198) (Subject)

    11/8/24 10:46:38 AM ET
    $FLR
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by General Motors Company (Amendment)

    SC 13G/A - General Motors Co (0001467858) (Subject)

    2/13/24 5:06:14 PM ET
    $GM
    Auto Manufacturing
    Industrials